Advertisement

Pharmaceutisch Weekblad

, Volume 8, Issue 1, pp 46–52 | Cite as

New 4-quinolones in the treatment of urinary tract infections

  • J. B. J. Boerema
Quinolones in Perspective

Abstract

The new fluorinated quinolones norfloxacin, ciprofloxacin and pefloxacin were evaluated in urinary infections. Bacteriological cure rates in both uncomplicated and complicated urinary tract infections ranged from 85% to 99%. Clinical cure rates were often lower due to the underlying conditions in the urinary tract. Patients with neurological bladder disease were cured in a relatively high percentage of theirPseudomonas infection after three months treatment with norfloxacin. Pharmacokinetics of ciprofloxacin in prostatic tissue and fluid will probably offer an advance in the treatment of chronic urinary infections due to an infectious prostatic focus. Definitely drug related side effects (of gastro-intestinal, neurological or allergic nature) were mild in most cases. The new 4-quinolones should be followed with interest concerning their activity in urological infections in general as well as specifically. The minor influence on the natural human flora and the possibility to decrease plasmid-mediated resistance are of major importance.

Key words

Ciprofloxacin Drug evaluation Norfloxacin Pefloxacin Prostatitis Side effects Urinary tract infections 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Roland AR, Turck M, Petersdorf RG. A critical evaluation of nalidixic acid in urinary tract infections. N Engl J Med 1966;275:1081–3.Google Scholar
  2. 2.
    Smith JT. Awaking the slumbering potential of the 4-quinolone antibacterials. Pharm J 1984;233:299–305.Google Scholar
  3. 3.
    Stamey TA, Bragonje J. Resistance to Nalidixic Acid. A misconception due to underdosage. JAMA 1976;236:1857–60.Google Scholar
  4. 4.
    Turgeon P, Dubois J, Stoffel S.In vitro activity of norfloxacin against 4003 clinical isolates: a multicentre study in Canada. Curr Ther Res 1985;38:169–72.Google Scholar
  5. 5.
    Bauernfeind A, Petermüller C.In vitro activity of ciprofloxacin. norfloxacin and nalidixic acid. Eur J Clin Microbiol 1983;2:111–5.Google Scholar
  6. 6.
    Barry AL, Jones RN, Thornsberry C, Avers LW, Gerlach EH, Sommers HM. Antibacterial activities of ciprofloxacin, norfloxacin. oxolinic acid. cinoxacin. and nalidixic acid. Antimicrob Agents Chemother 1984;25:633–7.Google Scholar
  7. 7.
    Fass RJ.In vitro activity of ciprofloxacin (Bay 09867). Antimicrob Agents Chemother 1983;24:568–74.Google Scholar
  8. 8.
    Wise R, Andrews JM, Edwards LJ.In vitro activity of Bay 09867. a new quinoline derivative compared with those of other antimicrobial agents. Antimicrob Agents Chemother 1983;23:559–64.Google Scholar
  9. 9.
    Reeves DS, Bijwater MJ, Holt HA, White LO.In vitro studies with ciprofloxacin. a new 4-quinolone compound. J Antimicrob Chemother 1984;13:333–46.Google Scholar
  10. 10.
    King A, Shannon K, Phillips I. Thein vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid. J Antimicrob Chemother 1984;13:325–31.Google Scholar
  11. 11.
    Willems FThC, Boerema JBJ, Van Summeren TRKM. Thein vitro comparative activity of quinolones against bacteria from urinary tract infections in general practice. J Antimicrob Chemother 1986;17:69–73.Google Scholar
  12. 12.
    Clarke AM, Zemcov SJV, Campbell ME.In vitro activity of pefloxacin compared to enoxacin. norfloxacin. gentamicin and new β-lactams. J Antimicrob Chemother 1985;15:39–44.Google Scholar
  13. 13.
    Kent AF, Speller DCE. Sensitivity of urinaryStaphylococci to ciprofloxacin and acrosoxacin. Eur J Clin Microbiol 1985;4:139–40.Google Scholar
  14. 14.
    Wolfson JS, Hooper DC. The fluoroquinolones: Structures, mechanisms of action and resistance, and spectra of activityin vitro. Antimicrob Agents Chemother 1985;28:581–6.Google Scholar
  15. 15.
    Hooper DC, Wolfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicity in humans. Antimicrob Agents Chemother 1985;28:716–21.Google Scholar
  16. 16.
    Holmes B, Brogden RN, Richards DM. Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1985;30:482–513.Google Scholar
  17. 17.
    Sabbour MS, El Blokl MA, Osman LM. Experiences on the efficacy and safety of nalidixic acid. oxolonic acid, cinoxacin and norfloxacin in the treatment of urinary tract infections (UTI). Infection 1984;12:377–80.Google Scholar
  18. 18.
    Hill S, Yeates M, Pathy J, Morgan JRS. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly. J Antimicrob Chemother 1985;15:505–8.Google Scholar
  19. 19.
    Watt B, Chait I, Kelsey MC. et al. Norfloxacin versus co-trimoxazole in the treatment of uncomplicated urinary tract infections — a multicentre trial. J Antimicrob Chemother 1984;13(suppl B):89–94.Google Scholar
  20. 20.
    Kirby CP. Treatment of simple urinary tract infection in general practice with a 3-day course of norfloxacin. J Antimicrob Chemother 1984;13(suppl B):107–12.Google Scholar
  21. 21.
    Vogel R, Deany NB, Round EM, Van den Burg MJ, Currie WJC. Norfloxacin, amoxycillin, co-trimoxazole and nalidixic acid. A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections. J Antimicrob Chemother 1984;13(suppl B):113–20.Google Scholar
  22. 22.
    Reeves DS, Lacey RW, Mummery RV, Mahendra M, Bint AJ, Newson SWB. Treatment of acute urinary tract infection by norfloxacin or nalidixic acid/citrate: a multicentre comparative study. J Antimicrob Chemother 1984;13(suppl B):99–105.Google Scholar
  23. 23.
    Goldstein EJC, Alpert ML, Ginsberg BP. Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections. Antimicrob Agents Chemother 1985;27:422–3.Google Scholar
  24. 24.
    Sabbaj J, Hoagland VL, Shih WJ. Multiclinical comparative study of norfloxacin and trimethoprim-sulfame-thoxazole for treatment of urinary tract infections. Antimicrob Agents Chemother 1985;27:297–301.Google Scholar
  25. 25.
    Boerema J, Boll B, Muytjens H, Branolte J. Efficacy and safety of ciprofloxacin (Bay 09867) in the treatment of patients with complicated urinary tract infections. J Antimicrob Chemother 1985;16:211–7.Google Scholar
  26. 26.
    Boerema JBJ, Verheggen W, Branolte J. Comparative efficacy and safety of ciprofloxacin and co-trimoxazole in the treatment of patients with complicated urinary tract infections. Eur J Clinical Microbiol (in press).Google Scholar
  27. 27.
    Boerema JBJ, Pouwels R. Scheepers J. Crombach W. Efficacy and safety of pefloxacin in the treatment of urinary tract infections. J Antimicrob Chemother (in press).Google Scholar
  28. 28.
    Wallmark G, Arremark I, Telander B.Stuphylococcus saprophylicus a frequent cause of acute urinary tract infection among female outpatients. J Infect Dis 1978;138:791–7.Google Scholar
  29. 29.
    Hovelius B, Mardh PA, Bygren P. Urinary tract infections caused byStaphylococcus saprophylicus: recurrences and complications. J Urol 1979;122:645–746.Google Scholar
  30. 30.
    Lewis RI, Carrion HM, Lockhart JI, Politano VA. Significance of asymptomatic bacteriuria in neurogenic bladder disease. Urology 1984;13:343–7.Google Scholar
  31. 31.
    Leigh DA, Emmanuel FXSD. The treatment ofPseudomonas aeruginosa urinary tract infections with norfloxacin. J Antimicrob Chemother 1984;13(suppl B):85–8.Google Scholar
  32. 32.
    Boerema JBJ. Long-term treatment of complicated UTI with norfloxacin. 4th Mediterranean Congress of Chemotherapy. Rhodos. October 19–25, 1984.Google Scholar
  33. 33.
    Winningham DG, Nemoy NJ, Stamey TA. Diffusion of antibiotics from plasma into prostatic fluid. Nature 1968;219:139–42.Google Scholar
  34. 34.
    Boerema JBJ, Dahlhoff A, Debruyne FMJ. Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy 1985;31:13–8.Google Scholar
  35. 35.
    Boerema JBJ, Debruyne FMJ, Dahlhoff A. Intraprostatic concentrations of ciprofloxacin after intravenous administration. Lancet 1984;2:695–6.Google Scholar
  36. 36.
    Bologna M, Vaggi L, Forchetti CM, Martini E. Bactericidal intra-prostatic concentrations of norfloxacin. Lancet 1983;2:280.Google Scholar
  37. 37.
    Chapman ST, Speller DCE, Reeves DS. Resistance to ciprofloxacin. Lancet 1985;2:39.Google Scholar
  38. 38.
    Humphreys H, Mulvihill E. Ciprofloxacin-resistantStaphylococcus aureus. Lancet 1985;2:383.Google Scholar
  39. 39.
    Smith GM, Cashmore C, Leyland MJ. Ciprofloxacin-resistantStaphylococci. Lancet 1985;2:949.Google Scholar
  40. 40.
    Smith JT. Mutational resistance to 4-quinolones antibacterial agents. Eur J Clin Microb 1984;3:347–50.Google Scholar
  41. 41.
    Bailey RR, Peddie BA, Blake E. Norfloxacin for the treatment of uncomplicated urinary tract infections. NZ Med J 1983;96:446.Google Scholar
  42. 42.
    Guerra JG, Falconi E, Palomino JC, Benavente L, Antunez de Mayolo E. Clinical evaluation of norfloxacin versus co-trimoxazole in urinary tract infections. Eur J Clin Microbiol 1983;2:260–5.Google Scholar
  43. 43.
    Giamarellou H, Tsagarakis J, Petrikkos G, Daikos GK. Norfloxacin versus co-trimoxazole infections. Eur J Clin Microbiol 1983;2:266–9.Google Scholar
  44. 44.
    Brumfitt W, Hamilton-Miller JMT. A review of the problem of urinary infection management and the evaluation of a potential new antibiotic. J Antimicrob Chemother 1984;13(suppl B):121–33.Google Scholar
  45. 45.
    Leigh DA, Smith EC, Marriner J. Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients. J Antimicrob Chemother 1984;13(suppl B):79–83.Google Scholar
  46. 46.
    Sauerwein D, Bauernfeind A. Klinische Erfahrungen bei Behandlung von Harnwegsinfekten bei Querschnittgelämtem mit Norfloxacin. Fortschr Antimikrob Antineoplast Chemother 1984;3–5:759–64.Google Scholar
  47. 47.
    Kummoto Y, Ishigami J. Clinical experience with norfloxacin in urinary tract infections. Eur J Chemother Antibiot 1983;3:31–9.Google Scholar
  48. 48.
    Weisser J, Wiedemann B. Elimination of plasmids by new 4-quinolones. J Antimicrob Chemother 1985;28:700–2.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1986

Authors and Affiliations

  • J. B. J. Boerema
    • 1
  1. 1.Medical Research BureauNY NijmegenThe Netherlands

Personalised recommendations